RHOEN-KLINIKUM AG (RHK.DE) Fundamental Analysis & Valuation

FRA:RHK • DE0007042301

Current stock price

12.5 EUR
0 (0%)
Last:

This RHK.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. RHK.DE Profitability Analysis

1.1 Basic Checks

  • RHK had positive earnings in the past year.
  • In the past year RHK had a positive cash flow from operations.
  • RHK had positive earnings in each of the past 5 years.
  • Each year in the past 5 years RHK had a positive operating cash flow.
RHK.DE Yearly Net Income VS EBIT VS OCF VS FCFRHK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • RHK has a Return On Assets of 2.02%. This is comparable to the rest of the industry: RHK outperforms 40.74% of its industry peers.
  • RHK's Return On Equity of 2.90% is on the low side compared to the rest of the industry. RHK is outperformed by 66.67% of its industry peers.
  • RHK has a worse Return On Invested Capital (2.67%) than 70.37% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 5.91%.
  • The 3 year average ROIC (2.34%) for RHK is below the current ROIC(2.67%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROIC 2.67%
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
RHK.DE Yearly ROA, ROE, ROICRHK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6

1.3 Margins

  • RHK has a Profit Margin (2.28%) which is in line with its industry peers.
  • In the last couple of years the Profit Margin of RHK has declined.
  • Looking at the Operating Margin, with a value of 2.86%, RHK is doing worse than 66.67% of the companies in the same industry.
  • RHK's Operating Margin has declined in the last couple of years.
  • RHK's Gross Margin of 66.81% is fine compared to the rest of the industry. RHK outperforms 70.37% of its industry peers.
  • RHK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
RHK.DE Yearly Profit, Operating, Gross MarginsRHK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RHK.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RHK is destroying value.
  • Compared to 1 year ago, RHK has about the same amount of shares outstanding.
  • RHK has about the same amout of shares outstanding than it did 5 years ago.
  • RHK has a better debt/assets ratio than last year.
RHK.DE Yearly Shares OutstandingRHK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RHK.DE Yearly Total Debt VS Total AssetsRHK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.04 indicates that RHK is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.04, RHK belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
  • RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • RHK's Debt to Equity ratio of 0.09 is amongst the best of the industry. RHK outperforms 96.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.04
ROIC/WACC0.41
WACC6.58%
RHK.DE Yearly LT Debt VS Equity VS FCFRHK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RHK has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 2.28, RHK belongs to the best of the industry, outperforming 96.30% of the companies in the same industry.
  • RHK has a Quick Ratio of 2.19. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
  • RHK's Quick ratio of 2.19 is amongst the best of the industry. RHK outperforms 96.30% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.19
RHK.DE Yearly Current Assets VS Current LiabilitesRHK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RHK.DE Growth Analysis

3.1 Past

  • RHK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.41%.
  • The Earnings Per Share has been growing slightly by 0.03% on average over the past years.
  • RHK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.10%.
  • The Revenue has been growing slightly by 4.12% on average over the past years.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.55% on average over the next years. This is quite good.
  • RHK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.92% yearly.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.55%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.92%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RHK.DE Yearly Revenue VS EstimatesRHK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B
RHK.DE Yearly EPS VS EstimatesRHK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

2

4. RHK.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • RHK is valuated rather expensively with a Price/Earnings ratio of 21.93.
  • Compared to the rest of the industry, the Price/Earnings ratio of RHK indicates a slightly more expensive valuation: RHK is more expensive than 66.67% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of RHK to the average of the S&P500 Index (25.23), we can say RHK is valued inline with the index average.
  • The Price/Forward Earnings ratio is 16.36, which indicates a correct valuation of RHK.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RHK indicates a slightly more expensive valuation: RHK is more expensive than 70.37% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of RHK to the average of the S&P500 Index (22.51), we can say RHK is valued slightly cheaper.
Industry RankSector Rank
PE 21.93
Fwd PE 16.36
RHK.DE Price Earnings VS Forward Price EarningsRHK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • RHK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RHK is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.14
RHK.DE Per share dataRHK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)5.1
PEG (5Y)644.88
EPS Next 2Y10.47%
EPS Next 3Y11.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. RHK.DE Dividend Analysis

5.1 Amount

  • RHK has a yearly dividend return of 0.80%, which is pretty low.
  • RHK's Dividend Yield is slightly below the industry average, which is at 1.96.
  • Compared to an average S&P500 Dividend Yield of 1.90, RHK's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.8%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
RHK.DE Yearly Dividends per shareRHK.DE Yearly Dividends per shareYearly Dividends per share 2019 2023 2025 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

  • 17.78% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
RHK.DE Yearly Income VS Free CF VS DividendRHK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M
RHK.DE Dividend Payout.RHK.DE Dividend Payout, showing the Payout Ratio.RHK.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RHK.DE Fundamentals: All Metrics, Ratios and Statistics

RHOEN-KLINIKUM AG

FRA:RHK (3/25/2026, 7:00:00 PM)

12.5

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)03-26
Inst Owners0.53%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap837.00M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (15.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.8%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 21.93
Fwd PE 16.36
P/S 0.51
P/FCF N/A
P/OCF 13.57
P/B 0.64
P/tB 0.74
EV/EBITDA 0.14
EPS(TTM)0.57
EY4.56%
EPS(NY)0.76
Fwd EY6.11%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.37%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.1
PEG (5Y)644.88
Graham Number15.78
Profitability
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROCE 3.25%
ROIC 2.67%
ROICexc 4.45%
ROICexgc 5.55%
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
FCFM N/A
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA 1.07
Cap/Depr 112.99%
Cap/Sales 4.21%
Interest Coverage 14.78
Cash Conversion 56.66%
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.19
Altman-Z 3.04
F-Score6
WACC6.58%
ROIC/WACC0.41
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.55%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.92%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y27.95%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%

RHOEN-KLINIKUM AG / RHK.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?

ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.


What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.


Can you provide the profitability details for RHOEN-KLINIKUM AG?

RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.


Can you provide the financial health for RHK stock?

The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.


How sustainable is the dividend of RHOEN-KLINIKUM AG (RHK.DE) stock?

The dividend rating of RHOEN-KLINIKUM AG (RHK.DE) is 2 / 10 and the dividend payout ratio is 17.78%.